ModifiedBlue Cross Blue Shield - TexasPolicy CPCPLAB049

General Inflammation Testing (CRP and ESR) Reimbursement

This policy describes reimbursement criteria for measurement of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) for various inflammatory conditions and the conditions under which testing is not reimbursable; it applies to providers submitting claims to Blue Cross Blue Shield of Texas.

Policy Summary

PayerBlue Cross Blue Shield - Texas

PolicyGeneral Inflammation Testing (CRP and ESR) Reimbursement

Policy CodePolicy CPCPLAB049

Change TypeCoverage wording, test preference rules, table updates, and code addition

Effective DateNov 7, 2025

Next Review DateN/A

Key ActionWhen either CRP or ESR are allowed, order CRP preferentially; if both are ordered where only one is allowed, only CRP will be allowed.

SourceLink

POLICY UPDATE CHANGES

Added Note 1 referencing CPCPLAB046 for the use of CRP as a cardiac biomarker, and CPCPLAB047 for the use of CRP as a marker for acute pancreatitis.

Removed 'inflammatory' from #1 as some conditions listed in Table 1 are noninflammatory, with measurement of CRP/ESR used to differentiate between a noninflammatory and inflammatory condition.

Revised Table 1 introduction to state coverage is designated based on the diagnosed or suspected inflammatory condition and that either conventional or high-sensitivity CRP testing are allowed; when either CRP or ESR are allowed, CRP is preferred and if both ordered only CRP will be allowed.

Within Table 1, added '(e.g., inflammatory bowel disease)' in the Frequency of Testing column for Irritable Bowel Syndrome and deleted the row specific to Giant Cell Arteritis; added Giant Cell Arteritis and Takayasu Arteritis under Large Vessel Vasculitis and changed Test Preference to CRP and ESR with specified monitoring frequency.

Added CPT/HCPCS code 86141 to the policy coding list.

References were revised following literature review.

Table of conditionsConditions with guidance (partial)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

CRP preferredCRP preferred when allowed

Not reimbursableNot reimbursable during general exam

ESR not reimbursableESR without diagnosed inflammatory condition

Table 1Table 1 revised

Conditions and Coverage Rules for CRP and ESR

Condition-specific coverage examples

Table 1 lists conditions with designation of allowed test (CRP, ESR, or both) and recommended testing frequency for active disease where specified.

ALL of the following

Test preference: CRP or ESR
Frequency: Not specified (NS)

ALL of the following

Test preference: CRP
Frequency: To confirm diagnosis; 2 to 3 days during the early therapeutic course; weekly until normalization (or a clear trend toward normalization is evident).

ALL of the following

Test preference: CRP
Frequency: Not specified (NS)

ALL of the following

Test preference: CRP and ESR
Frequency: Regular interval use in patients with active symptoms = 1-3 months initially; 6-12 months later.

ALL of the following

Test preference: CRP or ESR
Frequency: Not specified (NS)

ALL of the following

Test preference: CRP
Frequency: Not specified (NS)

ALL of the following

Test preference: ESR
Frequency: Every 3 to 6 months for 1 to 2 years; every 6 to 12 months for the next 3 years; annually thereafter.

ALL of the following

Test preference: CRP and ESR
Frequency: During initial assessment to exclude other diagnoses (e.g., inflammatory bowel disease).

ALL of the following

Test preference: CRP and ESR
Frequency: To confirm diagnosis; every 1-3 months during the first year; every 3-6 months thereafter.

ALL of the following

Test preference: CRP or ESR
Frequency: Regular interval use in patients with active symptoms.

ALL of the following

Test preference: CRP or ESR
Frequency: At initial diagnosis; every 3 months during long-term steroid therapy.

ALL of the following

Test preference: CRP and ESR
Frequency: Not specified (NS)

ALL of the following

Test preference: CRP or ESR
Frequency: Prior to treatment; every 1-3 months during active disease; annually when disease is inactive.

ALL of the following

Test preference: CRP or ESR
Frequency: At initial assessment; every 1-3 months during active disease; every 6-12 months during stable disease; during pregnancy.

ALL of the following

Test preference: ESR
Frequency: Not specified (NS)

Table 1 coverage rules (partial)

Summary of Table 1 and related coverage rules (partial extract from this document):

Coverage designation: Coverage of CRP, ESR, CRP or ESR, or both CRP and ESR is designated based on the diagnosed or suspected condition; some listed conditions may be noninflammatory and CRP/ESR may be used to differentiate between noninflammatory and inflammatory conditions.

Allowed CRP methods: Either conventional or high-sensitivity CRP testing are allowed methods of testing for CRP levels.

Test preference: When either CRP or ESR are allowed, CRP is the preferred biomarker.

Simultaneous ordering restriction: If CRP and ESR are ordered at the same time for a condition where CRP or ESR are allowed, only CRP will be allowed (billing restriction).

ESR restriction: For individuals without a diagnosed inflammatory condition, measurement of ESR is not reimbursable.

Procedure Codes and Testing Frequency Examples

Procedure codes (not exhaustive)mixed

The policy lists procedure codes but states the list is not all-encompassing and inclusion does not guarantee coverage.

Added codeCPTCovered

86141

C-reactive protein (CRP), quantification

Testing frequency examples

Acute Hematogenous Osteomyelitis (AHO)To confirm diagnosis; 2–3 days during the early therapeutic course; weekly until normalization (or a clear trend toward normalization is evident).

Rheumatoid ArthritisPrior to treatment; every 1–3 months during active disease; annually when disease is inactive.

Hodgkin LymphomaEvery 3–6 months for 1–2 years; every 6–12 months for the next 3 years; annually thereafter.

Large Vessel Vasculitis (Giant Cell Arteritis, Takayasu Arteritis)To confirm diagnosis; every 1–3 months during the first year; every 3–6 months thereafter.

Irritable Bowel SyndromeDuring initial assessment to exclude other diagnoses (e.g., inflammatory bowel disease).

Documentation, Billing, and Prior Authorization

Documentation Required

Documentation and claim submission

Providers are responsible for submission of accurate documentation of services performed and are expected to submit claims using valid code combinations from HIPAA-approved code sets. Claims are subject to code edit protocols and review against plan documents, provider contracts, medical policies, clinical payment and coding policies, and coding software logic; upon request, the provider is urged to submit any additional documentation.

Billing Rule

CRP preferred; simultaneous CRP+ESR orders restricted

When either CRP or ESR are allowed for a condition, CRP is the preferred biomarker; if CRP and ESR are ordered at the same time for a condition where CRP or ESR are allowed, only CRP will be allowed (billing restriction).

Added CPT/HCPCS code 86141 to the policy coding list (see coding table).

Test Preferences, Non-Reimbursable Uses, and Methods

CRP preference

Preference statementWhen CRP or ESR are allowed for a condition, CRP is the preferred biomarker.

Exclusive allowance when both orderedIf CRP and ESR are ordered at the same time for a condition where either is allowed, only CRP will be allowed (billing restriction).

ApplicabilityThis preference applies across indications listed in Table 1 and is part of the Table 1 introduction language.

Not reimbursable uses

ESR without diagnosisESR measurement is not reimbursable for individuals without a diagnosed inflammatory condition.

General examMeasurement of CRP and/or ESR during a general exam without abnormal findings is not reimbursable.

Policy Summary

PayerBlue Cross Blue Shield - Texas

PolicyGeneral Inflammation Testing (CRP and ESR) Reimbursement

Policy CodePolicy CPCPLAB049

Change TypeCoverage wording, test preference rules, table updates, and code addition

Effective DateNov 7, 2025

Next Review DateN/A

Key ActionWhen either CRP or ESR are allowed, order CRP preferentially; if both are ordered where only one is allowed, only CRP will be allowed.

SourceLink

On This Page

General exam restriction: Measurement of CRP and/or ESR during a general exam without abnormal findings is not reimbursable.

Table updates: Large Vessel Vasculitis row was updated to include Giant Cell Arteritis and Takayasu Arteritis with Test Preference = CRP and ESR and monitoring frequency to confirm diagnosis; every 1-3 months during the first year; every 3-6 months thereafter.

Testing preference rule

Primary ruleIf CRP or ESR are allowed for a condition, CRP is the preferred biomarker; when both are ordered at the same time for a condition where either is allowed, only CRP will be allowed.

Billing implicationSimultaneous orders for CRP and ESR when only one is indicated will result in CRP being the reimbursable test.

ScopeApplies to conditions listed in Table 1 where coverage is designated based on the diagnosed or suspected inflammatory condition.

Use limitationTesting must correspond to covered conditions in Table 1; routine screening is not supported.

CRP testing methods

Allowed methodsEither conventional or high-sensitivity CRP testing are allowed methods of testing for CRP levels.

Reference in Table 1 introThe Table 1 introduction explicitly states that either conventional or high-sensitivity CRP testing are allowed.

Implication for claimsClaims for CRP may be submitted using either testing method where CRP is the designated or preferred test.

Coverage designation

Basis for coverage designationCoverage designation in Table 1 is based on the diagnosed or suspected inflammatory condition (some listed conditions may be noninflammatory and CRP/ESR used to differentiate).

Table 1 roleTable 1 lists indications and specifies whether CRP, ESR, CRP or ESR, or both are designated for each condition.

Recent revisionsPolicy removed the word 'inflammatory' from #1 to reflect that some Table 1 conditions are noninflammatory; guidance updated accordingly.